news
Combination therapy facilitates optimal stem cell collection
Motixafortide plus standard stem cell therapy helped to “rapidly” mobilise stem cells in multiple myeloma, a Phase III trial has shown.
List view / Grid view
R&D
news
Merck to develop mAb through $10.8b acquisition
Through a $10.8 billion acquisition, Merck has agreed to buy Prometheus Biosciences to advance development of a novel monoclonal antibody for immune conditions.
news
Navigating delivery challenges of nucleic acid therapeutics
A paper has reviewed how novel drug delivery systems could achieve stable formulations of nucleic acid therapeutics.
article
Turning the TIDE: oligonucleotide development trends
Discover what is driving the oligonucleotide therapeutics sector as scientists navigate challenges such as financing and success-to-market.
news
Can automated buffer management systems overcome bioprocessing bottlenecks?
Researchers have developed a new automated buffer management system that offers supply to continuous downstream process for 10 days with consistent quality.
news
INTERPHEX 2023 – experience science through commercialisation
From development to distribution, leading global event Interphex 2023 (April 25-27 New York, US) takes you through all stages of the pharma product lifecycle.
article
Psychedelic medicines: are they gaining traction in Europe?
Carissa Kendall-Windless and Sian Banks of law firm Pinsent Masons discuss the development of psychedelic medicines and the legal and regulatory challenges that must be overcome for psychedelics to become safe and effective treatment options in Europe.
news
Biogen to develop amyloid beta-targeting antibody platform
The next-generation of anti- amyloid beta therapeutics could be advanced by Biogen exercising the option to develop Denali’s antibody programme.
news
Personalised blood pressure treatment shows efficacy
A study suggests that personalised blood pressure medication can "probably obtain better protection against future cardiovascular diseases".
article
ILAP: Improving access to innovative oncology treatments
With no new first-line treatment for de-differentiated liposarcoma in over forty years, Dr Christoph Zehendner, Medical Director of Boehringer Ingelheim UK and Ireland discusses the company’s ILAP designation of its investigational, innovative treatment.
news
Microbial fermentation tech market to exceed $56.9b by 2033
Trends such as sustainability and technological advances like AI are helping to boost the microbial fermentation technology market, a report says.
news
A review of MALDI-TOF for microbiological identification
Rapid identification of well-known bacterial species makes MALDI-TOF mass spectrometry a suitable alternative to conventional systems, researchers have stated.
news
Sustained-release chemotherapy has potential for bladder cancer
A study has shown an intravesical sustained-release chemotherapy device demonstrated effectiveness in advanced bladder cancer.
news
NICE guidance recommends olaparib for breast and prostate cancers
PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer.
news
Eculizumab biosimilar gets positive CHMP opinion
Samsung Bioepis’ first haematology biosimilar, which references Soliris (eculizumab), has been recommended for approval by the CHMP.
